

1 **Inducing Synergistic DNA Damage By TRIP13 And PARP1 Inhibitors Provides**

2 **A Potential Treatment For Hepatocellular Carcinoma**

3
4 **Supplementary Figure 1. TRIP13 promoted the growth of HCC *in vivo*.**

5 (A)TRIP13-knockdown (shTRIP13) or negative control (shNC) HCCLM3 cells were
6 inoculated subcutaneously into NOD-SCID mice. Tumor sizes were measured every
7 week. After 5 weeks of injection, the tumors were photographed and recorded
8 their weights. (B) HCCLM3 cells, including overexpression TRIP13 (pLenti-TRIP13)
9 and matched normal (pLenti-con), were orthotopic injected in liver tissues after
10 injected 5 weeks, mice have been tested the luciferase signals for each group. Data are
11 shown as mean \pm SEM. * p <0.05, *** p <0.001.

Figure S1

